PRECISION BIOSCIENCES Logo (WIPO, 18.11.2021)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke PRECISION BIOSCIENCES wurde als Bildmarke am 18.11.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Andere Textilien als Kleidung, Shuttles #Kreise #Briefe, die eine besondere Form des Schreibens darstellen #Bänder, Schleifen #Kreise mit dunklen Flächen oder Teilen von Flächen #Buchstabenreihen in verschiedenen Dimensionen
| Markenform | Bildmarke |
| Aktenzeichen | 1666433 |
| Länder | 
|
| Basismarke |
Nr. 97117510,
10. November 2021
|
| Anmeldedatum | 18. November 2021 |
| Ablaufdatum | 18. November 2031 |
Markeninhaber
302 East Pettigrew Street,
Dibrell Warehouse, Suite A-100
US
Dibrell Warehouse, Suite A-100
US
Markenvertreter
301 Fayetteville Street, Suite 1400
Raleigh NC 27601
US
Waren und Dienstleistungen
01
Genome editing reagents (term considered too vague by the
International Bureau - Rule 13 (2) (b) of the Regulations);
chemical, biochemical, biotechnological products intended
for industry, agriculture, horticulture, namely polypeptides
for in vivo and in vitro genetic engineering, natural and
engineered meganucleases and endonucleases, nucleic acid
vectors, molecular scissors; chemical, biochemical,
biotechnological and bacteriological products intended for
research laboratories and control laboratories, namely
polypeptides for in vivo and in vitro genetic engineering;
biochemicals and biologics, namely, engineered proteins for
gene regulation, genome engineering, gene modulation,
transcriptional regulation, transcriptional modulation, gene
modification, and gene correction, all for use in scientific
research, pharmaceutical research, agricultural
biotechnology, diagnostics, and industrial biotechnology;
engineered proteins for use in scientific research and
analysis relating to genetic diseases, gene therapy, and
cell therapy; biochemicals and biologics, namely, engineered
nucleic acids, viral vectors, non-viral vectors, gene
therapy vectors, gene editing vectors, genetically modified
cells, engineered proteins for multiplexed gene editing,
mRNA and recombinant adeno-associated virus (AAV) vectors
for delivery of therapeutic DNA or mRNA sequences to cells,
antibody preparations, CAR T-cell preparations, T-cell
preparations, B-cell preparations, Treg preparations, and NK
cell preparations, all for use in scientific research and
analysis and diagnostics
05
Pharmaceutical preparations, namely, cell therapy products
utilizing T-cell therapy for use in treating disease;
pharmaceuticals for the treatment of cancer; pharmaceutical
preparations in the nature of genetically modified cells,
namely genetically modified immune cells for use in human
therapeutics and in the treatment of cancer; pharmaceutical
and biological preparations based on gene, genome and
cellular editing, modulation, modification, engineering,
regulation, repair and therapy for use in human
therapeutics, namely, therapeutic pharmaceuticals developed
through genome modifications for the treatment of
cardiovascular, central nervous system, endocrine,
gastrointestinal, genetic immunological, infectious,
inflammatory, menopausal, metabolic, autoimmune,
musculoskeletal, neurological, ophthalmological,
psychiatric, respiratory, urogenital, urological,
hematologic and viral diseases and disorders; pharmaceutical
preparations, namely, therapeutic pharmaceuticals developed
through genome modifications for the treatment of erectile
dysfunction, sexual dysfunction, cancer, pain and diabetes;
pharmaceutical preparations, namely, therapeutic
pharmaceuticals developed through genome modifications,
namely, antifungal preparations, dermatological
preparations, smoking cessation preparations and tissue
repair preparations; engineered nucleic acids, viral
vectors, non-viral vectors, gene therapy vectors, gene
editing vectors, genetically modified cells, engineered
proteins for multiplexed gene editing, mRNA and recombinant
adeno-associated virus (AAV) vectors for delivery of
therapeutic DNA or mRNA sequences to cells, antibody
preparations, CAR T-cell preparations, T-cell preparations,
B-cell preparations, Treg preparations, and NK cell
preparations, all for clinical use, medical use, clinical
laboratory use, and medical laboratory use
42
Research in the fields of genome editing, gene editing,
genome engineering, gene modulation, transcriptional
regulation, transcriptional modulation, genetic disease,
gene therapy and cell therapy; pharmaceutical research and
development services; scientific and industrial research;
research in genetic, medical, pharmaceutical and veterinary
fields; research in chemistry, biology, biochemistry,
molecular biology, bacteriology; scientific analysis
44
Cellular immunotherapy programs utilizing chimeric antigen
receptor t cells for use in treating disease, namely, the
treatment of cancer; cell-based immunotherapeutic treatment
by way of genetically modified cells for use in human
therapeutics and the treatment of cancer
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 05. Juni 2023 | 2023/24 Gaz | CN | Ablehnung |
| 20. April 2023 | 2023/16 Gaz | JP | Ablehnung |
| 10. März 2023 | 2023/10 Gaz | GB | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 09. Februar 2023 | 2023/7 Gaz | GB | Ablehnung |
| 26. Januar 2023 | 2023/8 Gaz | EM | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 23. Juni 2022 | 2022/27 Gaz | AU | Ablehnung |
| 21. Juni 2022 | 2022/26 Gaz | EM | Ablehnung |
| 18. November 2021 | 2022/22 Gaz | US | Eintragung |
ID: 141666433